Gene-Targeting of Phd2 Improves Tumor Response to Chemotherapy and Prevents Side-Toxicity

Cancer Cell

Volumn 22, Issue 2, 2012, Pages 263-277

  Leite de Oliveira, Rodrigo ^a,b   Deschoemaeker, Sofie ^a,b   Henze, Anne Theres ^a,b   Debackere, Koen ^a,b   Finisguerra, Veronica ^a,b   Takeda, Yukiji ^a,b   Roncal, Carmen ^a,b,c   Dettori, Daniela ^a,b   Tack, Evelyne ^a,b   Jönsson, Yannick ^a,b   Veschini, Lorenzo ^a,b   Peeters, Annelies ^d   Anisimov, Andrey ^e   Hofmann, Matthias ^f   Alitalo, Kari ^e   Baes, Myriam ^d   D'hooge, Jan ^b   Carmeliet, Peter ^a,b   Mazzone, Massimiliano ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF NAVARRA   (Spain)

^d DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^e UNIVERSITY OF HELSINKI   (Finland)

^f GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR; PROLYL HYDROXYLASE DOMAIN PROTEIN 2; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DETOXIFICATION; GENE TARGETING; LEWIS CARCINOMA; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TISSUE INJURY;

EID: 84865107849     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.06.028     Document Type: Article

References (57)

1. Ameln A.K., Muschter A., Mamlouk S., Kalucka J., Prade I., Franke K., Rezaei M., Poitz D.M., Breier G., Wielockx B. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFβ. Cancer Res. 2011, 71:3306-3316.
2. Andersen S., Donnem T., Stenvold H., Al-Saad S., Al-Shibli K., Busund L.T., Bremnes R.M. Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS ONE 2011, 6:e23847.
3. Anisimov A., Alitalo A., Korpisalo P., Soronen J., Kaijalainen S., Leppänen V.M., Jeltsch M., Ylä-Herttuala S., Alitalo K. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ. Res. 2009, 104:1302-1312.
4. Anscher M.S., Chen L., Rabbani Z., Kang S., Larrier N., Huang H., Samulski T.V., Dewhirst M.W., Brizel D.M., Folz R.J., Vujaskovic Z. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:255-259.
5. Aragonés J., Jones D.R., Martin S., San Juan M.A., Alfranca A., Vidal F., Vara A., Mérida I., Landázuri M.O. Evidence for the involvement of diacylglycerol kinase in the activation of hypoxia-inducible transcription factor 1 by low oxygen tension. J. Biol. Chem. 2001, 276:10548-10555.
6. Aragonés J., Schneider M., Van Geyte K., Fraisl P., Dresselaers T., Mazzone M., Dirkx R., Zacchigna S., Lemieux H., Jeoung N.H., et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat. Genet. 2008, 40:170-180.
7. Aragonés J., Fraisl P., Baes M., Carmeliet P. Oxygen sensors at the crossroad of metabolism. Cell Metab. 2009, 9:11-22.
8. Berthiaume J.M., Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 2007, 23:15-25.
9. Bertout J.A., Majmundar A.J., Gordan J.D., Lam J.C., Ditsworth D., Keith B., Brown E.J., Nathanson K.L., Simon M.C. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc. Natl. Acad. Sci. USA 2009, 106:14391-14396.
10. Bordoli M.R., Stiehl D.P., Borsig L., Kristiansen G., Hausladen S., Schraml P., Wenger R.H., Camenisch G. Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis. Oncogene 2011, 30:548-560.
11. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
12. Chan D.A., Kawahara T.L., Sutphin P.D., Chang H.Y., Chi J.T., Giaccia A.J. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009, 15:527-538.
13. D'Adamo D.R., Anderson S.E., Albritton K., Yamada J., Riedel E., Scheu K., Schwartz G.K., Chen H., Maki R.G. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 2005, 23:7135-7142.
14. Date T., Mochizuki S., Belanger A.J., Yamakawa M., Luo Z., Vincent K.A., Cheng S.H., Gregory R.J., Jiang C. Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. Am. J. Physiol. Cell Physiol. 2005, 288:C314-C320.
15. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci. USA 2011, 108:1850-1855.
16. Eckle T., Köhler D., Lehmann R., El Kasmi K., Eltzschig H.K. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 2008, 118:166-175.
17. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
18. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
19. Fraisl P., Aragonés J., Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat. Rev. Drug Discov. 2009, 8:139-152.
20. Gerald D., Berra E., Frapart Y.M., Chan D.A., Giaccia A.J., Mansuy D., Pouyssegur J., Yaniv M., Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004, 118:781-794.
21. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., Jain R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91:1071-1121.
22. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
23. Hofmann M., Guschel M., Bernd A., Bereiter-Hahn J., Kaufmann R., Tandi C., Wiig H., Kippenberger S. Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. Neoplasia 2006, 8:89-95.
24. Huang M., Chan D.A., Jia F., Xie X., Li Z., Hoyt G., Robbins R.C., Chen X., Giaccia A.J., Wu J.C. Short hairpin RNA interference therapy for ischemic heart disease. Circulation 2008, 118(14, Suppl):S226-S233.
25. Hyvärinen J., Hassinen I.E., Sormunen R., Mäki J.M., Kivirikko K.I., Koivunen P., Myllyharju J. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J. Biol. Chem. 2010, 285:13646-13657.
26. Jain K.K. Advances in the field of nanooncology. BMC Med. 2010, 8:83.
27. Kamphues C., Wittschieber D., Klauschen F., Kasajima A., Dietel M., Schmidt S.C., Glanemann M., Bahra M., Neuhaus P., Weichert W., Stenzinger A. Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer. Pathobiology 2012, 79:11-17.
28. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
29. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., Cornell-Kennon S., Lee J., Wang B., Wang J., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004, 6:33-43.
30. Lee K.A., Lynd J.D., O'Reilly S., Kiupel M., McCormick J.J., LaPres J.J. The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. Mol. Cancer Res. 2008, 6:829-842.
31. Lee P.J., Jiang B.H., Chin B.Y., Iyer N.V., Alam J., Semenza G.L., Choi A.M. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J. Biol. Chem. 1997, 272:5375-5381.
32. Loges S., Mazzone M., Hohensinner P., Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009, 15:167-170.
33. Martin F., Linden T., Katschinski D.M., Oehme F., Flamme I., Mukhopadhyay C.K., Eckhardt K., Tröger J., Barth S., Camenisch G., Wenger R.H. Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood 2005, 105:4613-4619.
34. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., Tian Y.M., Lanahan A.A., Pollard P., Ruiz de Almodovar C., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
35. Minamishima Y.A., Moslehi J., Bardeesy N., Cullen D., Bronson R.T., Kaelin W.G. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008, 111:3236-3244.
36. Minamishima Y.A., Moslehi J., Padera R.F., Bronson R.T., Liao R., Kaelin W.G. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol. Cell. Biol. 2009, 29:5729-5741.
37. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
38. Mukhopadhyay C.K., Mazumder B., Fox P.L. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J. Biol. Chem. 2000, 275:21048-21054.
39. Nakasone E.S., Askautrud H.A., Kees T., Park J.H., Plaks V., Ewald A.J., Fein M., Rasch M.G., Tan Y.X., Qiu J., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.
40. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73:994-1007.
41. Paterna J.C., Moccetti T., Mura A., Feldon J., Büeler H. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther. 2000, 7:1304-1311.
42. Peurala E., Koivunen P., Bloigu R., Haapasaari K.M., Jukkola-Vuorinen A. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res. Treat. 2012, 133:179-188.
43. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
44. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., Squadrito M.L., Segura I., Li X., Knevels E., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
45. Schneider M., Van Geyte K., Fraisl P., Kiss J., Aragonés J., Mazzone M., Mairbäurl H., De Bock K., Jeoung N.H., Mollenhauer M., et al. Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. Gastroenterology 2010, 138:1143-1154.
46. Scortegagna M., Ding K., Oktay Y., Gaur A., Thurmond F., Yan L.J., Marck B.T., Matsumoto A.M., Shelton J.M., Richardson J.A., et al. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat. Genet. 2003, 35:331-340.
47. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
48. Shokolenko I., Venediktova N., Bochkareva A., Wilson G.L., Alexeyev M.F. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res. 2009, 37:2539-2548.
49. Stockmann C., Doedens A., Weidemann A., Zhang N., Takeda N., Greenberg J.I., Cheresh D.A., Johnson R.S. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818.
50. Su Y., Loos M., Giese N., Metzen E., Büchler M.W., Friess H., Kornberg A., Büchler P. Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer. Cancer 2012, 118:960-972.
51. Takeda K., Cowan A., Fong G.H. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 2007, 116:774-781.
52. Takeda Y., Costa S., Delamarre E., Roncal C., Leite de Oliveira R., Squadrito M.L., Finisguerra V., Deschoemaeker S., Bruyère F., Wenes M., et al. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 2011, 479:122-126.
53. Unnikrishnan A., Raffoul J.J., Patel H.V., Prychitko T.M., Anyangwe N., Meira L.B., Friedberg E.C., Cabelof D.C., Heydari A.R. Oxidative stress alters base excision repair pathway and increases apoptotic response in apurinic/apyrimidinic endonuclease 1/redox factor-1 haploinsufficient mice. Free Radic. Biol. Med. 2009, 46:1488-1499.
54. Van der Veldt A.A., Lubberink M., Bahce I., Walraven M., de Boer M.P., Greuter H.N., Hendrikse N.H., Eriksson J., Windhorst A.D., Postmus P.E., et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012, 21:82-91.
55. Vengellur A., Woods B.G., Ryan H.E., Johnson R.S., LaPres J.J. Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1alpha null mouse embryonic fibroblasts. Gene Expr. 2003, 11:181-197.
56. Vengellur A., Grier E., Lapres J.J. The Loss of HIF1α Leads to Increased Susceptibility to Cadmium-Chloride-Induced Toxicity in Mouse Embryonic Fibroblasts. J. Toxicol. 2011, 2011:391074.
57. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.